TY - JOUR
T1 - CT Imaging Assessment of Pancreatic Adenocarcinoma Resectability after Neoadjuvant Therapy
T2 - Current Status and Perspective on the Use of Radiomics
AU - Khasawneh, Hala
AU - Ferreira Dalla Pria, Hanna Rafaela
AU - Miranda, Joao
AU - Nevin, Rachel
AU - Chhabra, Shalini
AU - Hamdan, Dina
AU - Chakraborty, Jayasree
AU - Biachi de Castria, Tiago
AU - Horvat, Natally
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/11
Y1 - 2023/11
N2 - Pancreatic adenocarcinoma (PDAC) is the most common pancreatic cancer and is associated with poor prognosis, a high mortality rate, and a substantial number of healthy life years lost. Surgical resection is the primary treatment option for patients with resectable disease; however, only 10–20% of all patients with PDAC are eligible for resection at the time of diagnosis. In this context, neoadjuvant therapy has the potential to increase the number of patients who are eligible for resection, thereby improving the overall survival rate. For patients who undergo neoadjuvant therapy, computed tomography (CT) remains the primary imaging tool for assessing treatment response. Nevertheless, the interpretation of imaging findings in this context remains challenging, given the similarity between viable tumor and treatment-related changes following neoadjuvant therapy. In this review, following an overview of the various treatment options for PDAC according to its resectability status, we will describe the key challenges regarding CT-based evaluation of PDAC treatment response following neoadjuvant therapy, as well as summarize the literature on CT-based evaluation of PDAC treatment response, including the use of radiomics. Finally, we will outline key recommendations for the management of PDAC after neoadjuvant therapy, taking into consideration CT-based findings.
AB - Pancreatic adenocarcinoma (PDAC) is the most common pancreatic cancer and is associated with poor prognosis, a high mortality rate, and a substantial number of healthy life years lost. Surgical resection is the primary treatment option for patients with resectable disease; however, only 10–20% of all patients with PDAC are eligible for resection at the time of diagnosis. In this context, neoadjuvant therapy has the potential to increase the number of patients who are eligible for resection, thereby improving the overall survival rate. For patients who undergo neoadjuvant therapy, computed tomography (CT) remains the primary imaging tool for assessing treatment response. Nevertheless, the interpretation of imaging findings in this context remains challenging, given the similarity between viable tumor and treatment-related changes following neoadjuvant therapy. In this review, following an overview of the various treatment options for PDAC according to its resectability status, we will describe the key challenges regarding CT-based evaluation of PDAC treatment response following neoadjuvant therapy, as well as summarize the literature on CT-based evaluation of PDAC treatment response, including the use of radiomics. Finally, we will outline key recommendations for the management of PDAC after neoadjuvant therapy, taking into consideration CT-based findings.
KW - computed tomography
KW - neoadjuvant therapy
KW - pancreatic cancer
KW - radiomics
KW - treatment response
UR - http://www.scopus.com/inward/record.url?scp=85176565418&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176565418&partnerID=8YFLogxK
U2 - 10.3390/jcm12216821
DO - 10.3390/jcm12216821
M3 - Review article
C2 - 37959287
AN - SCOPUS:85176565418
SN - 2077-0383
VL - 12
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 21
M1 - 6821
ER -